Management of epilepsy in tuberous sclerosis complex

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.8.3.457PMID 18345974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Visual Fields in Children Treated With Vigabatrin

  2008cited by this paper
• Mechanisms of Epileptogenesis in Tuberous Sclerosis Complex and Related Malformations of Cortical Development with Abnormal Glioneuronal Proliferation

  2008cited by this paper
• The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment.

  2007cited by this paper
• Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex.

  2007cited by this paper
• Combined Ketogenic Diet and Vagus Nerve Stimulation: Rational Polytherapy?

  2007cited by this paper
• Epilepsy Surgery in Tuberous Sclerosis: A Systematic Review

  2007cited by this paper
• Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1

  2007cited by this paper
• Current role of vigabatrin in infantile spasms.

  2007cited by this paper
• Neuroimaging in tuberous sclerosis complex

  2007cited by this paper
• The tuberous sclerosis complex.

  2006cited by this paper
• A role for the mTOR pathway in surface expression of AMPA receptors.

  2006cited by this paper
• Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.

  2006cited by this paper
• Current management for epilepsy in tuberous sclerosis complex

  2006cited by this paper
• Molecular and clinical analyses of 84 patients with tuberous sclerosis complex

  2006cited by this paper
• Anomalous Inhibitory Circuits in Cortical Tubers of Human Tuberous Sclerosis Complex Associated With Refractory Epilepsy: Aberrant Expression of Parvalbumin and Calbindin-D28k in Dysplastic Cortex

  2006cited by this paper
• Vigabatrin Retinopathy in an Irish Cohort: Lack of Correlation with Dose

  2006cited by this paper
• Vagus nerve stimulation: clinical experience in drug-resistant pediatric epileptic patients.

  2006cited by this paper
• Roles of Glutamate Receptors and the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Activity-dependent Dendritic Protein Synthesis in Hippocampal Neurons*

  2006cited by this paper
• Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

  2006cited by this paper
• Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex.

  2006cited by this paper
• Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland

  2006cited by this paper
• The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication

  2006cited by this paper
• Longitudinal MR findings in a patient with hemimegalencephaly associated with tuberous sclerosis.

  2005cited by this paper
• Disruption of Interneuron Development

  2005cited by this paper
• The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication

  2005cited by this paper
• Taylor‐type Focal Cortical Dysplasia in Infants: Some MRI Lesions Almost Disappear with Maturation of Myelination

  2005cited by this paper
• Consistent Localization of Interictal Epileptiform Activity on EEGs of Patients with Tuberous Sclerosis Complex

  2005cited by this paper
• Characterizing Magnetoencephalographic Spike Sources in Children with Tuberous Sclerosis Complex

  2005cited by this paper
• Evidence‐based Treatment of Idiopathic Generalized Epilepsies with New Antiepileptic Drugs

  2005cited by this paper
• Tuberous Sclerosis Complex and the Ketogenic Diet

  2005cited by this paper
• Epilepsy Surgery Outcome in Children With Tuberous Sclerosis Complex Evaluated With α-[11C]Methyl-L-Tryptophan Positron Emission Tomography (PET)

  2005cited by this paper
• Dysfunction of Synaptic Inhibition in Epilepsy Associated with Focal Cortical Dysplasia

  2005cited by this paper
• Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype – phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex

  2005cited by this paper
• Proton Spectroscopic Findings in Children With Epilepsy Owing to Tuberous Sclerosis Complex

  2005cited by this paper
• Identification of candidates for epilepsy surgery in patients with tuberous sclerosis

  2005cited by this paper
• Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders.

  2004cited by this paper
• Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.

  2004cited by this paper
• Long-term outcome of epilepsy surgery in patients with tuberous sclerosis

  2004cited by this paper
• Mouse Models of Tuberous Sclerosis Complex

  2004cited by this paper
• Epilepsy Surgery for Children With Tuberous Sclerosis Complex

  2004cited by this paper
• Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

  2004cited by this paper
• Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin

  2004cited by this paper
• Standardized Whole Brain Mapping of Tubers and Subependymal Nodules in Tuberous Sclerosis Complex

  2004cited by this paper
• Tuberous sclerosis complex: from basic science to clinical phenotypes

  2004cited by this paper
• Scotopic threshold response changes after vigabatrin therapy in a child without visual field defects: a new electroretinographic marker of early damage?

  2004cited by this paper
• Tuberous Sclerosis and Multiple Tubers: Localizing the Epileptogenic Zone

  2004cited by this paper
• The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex

  2004cited by this paper
• Increased brain apparent diffusion coefficient in tuberous sclerosis.

  2004cited by this paper
• Molecular Pathogenesis of Tuber Formation in Tuberous Sclerosis Complex

  2004cited by this paper
• Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment

  2004cited by this paper
• Brain Abnormalities in Tuberous Sclerosis Complex

  2004cited by this paper
• Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation of TSC1 or TSC2 Leads to mTOR Activation

  2004cited by this paper
• Integrative classification of morphology and molecular genetics in central nervous system malformations

  2004cited by this paper
• Managing Epilepsy in Tuberous Sclerosis Complex

  2004cited by this paper
• Epilepsy surgery for tuberous sclerosis.

  2004cited by this paper
• The tuberous sclerosis complex and its highly variable manifestations.

  2003cited by this paper
• Visual field defects in pediatric patients on vigabatrin monotherapy

  2003cited by this paper
• GABAA receptor active steroids are altered in epilepsy patients with tuberous sclerosis

  2003cited by this paper
• Characterization of vigabatrin-associated optic atrophy.

  2003cited by this paper
• Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model

  2003cited by this paper
• Examining visual field defects in the paediatric population exposed to vigabatrin

  2003cited by this paper
• Epilepsy Surgery in Tuberous Sclerosis: Multistage Procedures With Bilateral or Multilobar Foci

  2002cited by this paper
• Visual Field Constriction in 91 Finnish Children Treated with Vigabatrin

  2002cited by this paper
• Characteristics of epilepsy in focal cortical dysplasia in infancy.

  2002cited by this paper
• TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/TSC2 frequency ratios

  2002cited by this paper
• Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome.

  2002cited by this paper
• Tuberous sclerosis complex: a review of neurological aspects.

  2002cited by this paper
• Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children

  2002cited by this paper
• Étude du champ visuel et traitement par vigabatrin chez l'enfant

  2001cited by this paper
• Visual field loss associated with vigabatrin: pathological correlations

  2001cited by this paper
• Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers

  2001cited by this paper
• Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

  2001cited by this paper
• Reversed visual field constrictions in children after vigabatrin withdrawal--true retinal recovery or improved test performance only?

  2001cited by this paper
• [Study of visual field and vigabatrin treatment in children].

  2001cited by this paper
• Vagal nerve stimulation in tuberous sclerosis complex patients.

  2001cited by this paper
• Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

  2000cited by this paper
• [Acute psychotic disorder associated with vigabatrin].

  2000cited by this paper
• Vigabatrin-associated visual field defects in children

  2000cited by this paper
• Separating the retinal electrophysiologic effects of vigabatrin

  2000cited by this paper
• Visual impairment in children with epilepsy treated with vigabatrin

  2000cited by this paper
• Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?

  2000cited by this paper
• Separating the retinal electrophysiologic effects of vigabatrin. treatment versus field loss

  2000cited by this paper
• Visual Field Constriction in Children With Epilepsy on Vigabatrin Treatment

  2000cited by this paper
• Visual field defects associated with vigabatrin monotherapy in children

  2000cited by this paper
• Electro‐Oculography, Electroretinography, Visual Evoked Potentials, and Multifocal Electroretinography in Patients with Vigabatrin‐Attributed Visual Field Constriction

  2000cited by this paper
• Visual field defects associated with vigabatrin therapy

  1999cited by this paper
• Physiological modulation of GABA(A) receptor plasticity by progesterone metabolites.

  1999cited by this paper
• Reversibility of vigabatrin-induced visual-field defect

  1999cited by this paper
• Characteristics of a Unique Visual Field Defect Attributed to Vigabatrin

  1999cited by this paper
• Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.

  1999cited by this paper
• Topical Review: Vigabatrin in the Treatment of Infantile Spasms in Tuberous Sclerosis: Literature Review

  1999cited by this paper
• Imaging epileptogenic tubers in children with tuberous sclerosis complex usingα‐[11C]Methyl‐L‐tryptophan positron emission tomography

  1998cited by this paper
• Vigabatrin-associated retinal cone system dysfunction

  1998cited by this paper
• Vigabatrin-associated retinal cone system dysfunction

  1998cited by this paper
• Prevalence of tuberous sclerosis estimated by capture-recapture analysis.

  1998cited by this paper
• Frontal Lobe Epilepsy Associated With Tuberous Sclerosis: Electroencephalographic-Magnetic Resonance Image Fusioning

  1998cited by this paper
• Severe persistent visual field constriction associated with vigabatrin

  1997cited by this paper
• Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.

  1997cited by this paper
• Neurochemical Profile of Glioneuronal Lesions from Patients with Pharmacoresistant Focal Epilepsies

  1995cited by this paper
• Sleep disorders in tuberous sclerosis: a polysomnographic study.

  1995cited by this paper

• Diagnostic flow analysis of tuberous sclerosis complex in Japan: a retrospective claims database study

  2024cites this paper
• G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling

  2021cites this paper
• G3BP1 tethers the TSC complex to lysosomes and suppresses mTORC1 in the absence of stress granules

  2020cites this paper
• MRI-guided laser interstitial thermal therapy in an infant with tuberous sclerosis: technical case report.

  2019cites this paper
• Increased matrix metalloproteinases expression in tuberous sclerosis complex: modulation by microRNA 146a and 147b in vitro

  2019cites this paper
• Novel therapies for epilepsy in the pipeline.

  2019cites this paper
• [Clinical and genetic study patients with tuberous sclerosis complex].

  2017cites this paper
• 45 – Phakomatoses and Allied Conditions

  2017cites this paper
• Kainic Acid Induces mTORC1-Dependent Expression of Elmo1 in Hippocampal Neurons

  2016cites this paper
• Update of Treatment for Children of tuberous sclerosis complex

  2015cites this paper
• Capítulo 14 – Genética de la neoplasia endocrina múltiple

  2015cites this paper
• Mouse hippocampal phosphorylation footprint induced by generalized seizures: Focus on ERK, mTORC1 and Akt/GSK-3 pathways.

  2015cites this paper
• Complications of epilepsy surgery

  2015cites this paper
• Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies.

  2015cites this paper
• Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments

  2015cites this paper
• Хирургическое лечение эпилепсии у пациентов с туберозным склерозом

  2015cites this paper
• EPILEPSY SURGERY IN PATIENTS WITH TUBEROUS SCLEROSIS

  2015cites this paper
• Aplicación de la tomografía por emisíón de positrones cerebral con dilerentes radiotrazadores en la valoración prequirúrgica de pacientes con epilepsia

  2014cites this paper
• The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

  2014cites this paper
• Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options

  2014cites this paper
• Towards early diagnosis and treatment to save children from catastrophic epilepsy -- focus on epilepsy surgery.

  2013cites this paper
• Resource Utilization in Children With Tuberous Sclerosis Complex and Associated Seizures

  2013cites this paper
• Neurogenetic Disorders and Treatment of Associated Seizures

  2013cites this paper
• Review article Towards early diagnosis and treatment to save children from catastrophic epilepsy - Focus on epilepsy surgery q

  2013cites this paper
• Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex

  2013influential citation
• Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex

  2013cites this paper
• Epilepsy neurosurgery in children.

  2012cites this paper
• Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis

  2012cites this paper
• Epilepsy and skin anomalies in tuberous sclerosis complex: Report of five cases and review of the sub-Saharan African literature

  2012cites this paper
• Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis

  2011cites this paper
• Treatment of Infantile Spasms

  2011cites this paper
• Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review

  2011cites this paper
• Coagulation abnormalities in children undergoing epilepsy surgery.

  2011cites this paper
• Targeting mTOR complex 1 to treat neurological and psychiatric manifestations of tuberous sclerosis complex

  2011cites this paper
• Epilepsy surgery in tuberous sclerosis complex: Emphasis on surgical candidate and neuropsychology

  2010cites this paper
• Epilepsy in TSC

  2010cites this paper
• Not for Sale or Commercial Distribution

  2007cites this paper